# Pre-Mortem Analysis: Deutsche Bank AG

**Bank ID**: deutsche-bank
**Phase**: 1 - European Tier 1
**Date**: 2025-12-21
**Prior P(Architect)**: 40%

---

## 1. Research Objective

**Primary Goal**: Validate 'Pilot; production expected 2025' claim from framework v20

**Key Questions**:
1. Has Deutsche Bank announced any CDM/DRR pilot or production timeline?
2. Is Deutsche Bank contributing to CDM development at ISDA or FINOS?
3. How did Deutsche Bank address EMIR Refit (April 2024)?
4. Are regulatory enforcement priorities consuming technology capacity?
5. What do named individuals say about derivatives technology direction?

---

## 2. Potential Failure Modes

### 2.1 False Positive Risks (Incorrectly classifying as ARCHITECT)

| Risk | Description | Mitigation |
|------|-------------|------------|
| **Vendor marketing conflation** | Vendor claims Deutsche Bank as CDM client without bank confirmation | Require bank-side confirmation per CLAUDE.md Section 5 |
| **Working group membership overweighting** | ISDA membership ≠ production adoption | Classify as `membership_or_participation` only |
| **Historical participation decay** | 2018-2019 pilot participation may not reflect current state | Apply temporal weight (0.5 for dated evidence) |
| **Innovation PR vs. reality** | Press releases about "digital transformation" without CDM specificity | Require explicit CDM/DRR mention |
| **German language barrier** | Missing German-language announcements | Include "Derivateberichterstattung" searches |

### 2.2 False Negative Risks (Incorrectly classifying as PRAGMATIST)

| Risk | Description | Mitigation |
|------|-------------|------------|
| **Swiss discretion norms** | German banks may also practice discretion about technology investments | Check FINOS/ISDA repos before assuming absence |
| **Regulatory enforcement noise** | Recent enforcement actions may overshadow positive CDM news | Separate enforcement from CDM research |
| **Capacity constraints assumption** | Assuming enforcement = no CDM capacity without evidence | Require explicit evidence of either path |
| **BaFin requirements unknown** | German regulator CDM position unclear | Research BaFin derivatives reporting requirements |

### 2.3 Evidence Quality Risks

| Risk | Description | Mitigation |
|------|-------------|------------|
| **Stale evidence** | 2018/2019 DerivHack participation doesn't indicate 2025 status | Require current (< 12 months) evidence for high confidence |
| **Single source dependency** | All evidence from one vendor or press outlet | Require corroboration per triangulation mandate |
| **Paywalled sources** | Risk.net, FT content may be inaccessible | Note as paywalled null result if applicable |

---

## 3. Search Strategy Adjustments

### 3.1 German-Specific Considerations

Per `knowledge_base/negative_facts.md` Section A:
- Include German terms: "Deutsche Bank Derivateberichterstattung" (derivatives reporting)
- Check German trade publications (Börsen-Zeitung, Handelsblatt)
- BaFin regulatory filings may be in German

### 3.2 Regulatory Context

Deutsche Bank has faced significant regulatory enforcement:
- Monitor for evidence that enforcement is DRIVING CDM investment (positive)
- Monitor for evidence that enforcement is CONSUMING capacity (negative)
- The manifest notes "enforcement_direction": "unclear"

### 3.3 EMIR Refit Response (Critical)

EMIR Refit effective April 2024 - Deutsche Bank MUST have addressed this:
- Did they use CDM for EMIR Refit compliance?
- Did they use traditional approach?
- This is a differentiating question

---

## 4. Prior Probability Rationale

| Factor | Adjustment | Rationale |
|--------|------------|-----------|
| Base prior | 30% | Default for unknown banks |
| Derivatives dominant | +10% | High derivatives relevance per manifest |
| Regulatory enforcement | 0% | Direction unclear - could go either way |
| **Calculated Prior** | **40%** | Starting point for Bayesian updates |

---

## 5. Success Criteria

### Minimum Evidence for Classification

| Classification | Required Evidence |
|----------------|-------------------|
| ARCHITECT-Native | Tier 1 evidence of production usage |
| ARCHITECT-Leader | Tier 1/2 evidence of pilot with timeline |
| ARCHITECT-Follower | Tier 1/2 evidence of FINOS contribution or working group leadership |
| PRAGMATIST | Absence of above OR explicit vendor-only strategy |

### Confidence Thresholds

- **High confidence (>75%)**: Requires Tier 1 evidence with current recency
- **Medium confidence (50-75%)**: Tier 2 evidence with corroboration
- **Low confidence (<50%)**: Tier 3 only or conflicting evidence

---

## 6. Abort Criteria

Research should be flagged for human review if:
- Combined LR exceeds 100 or falls below 0.01 (extreme values)
- Contradictory Tier 1 evidence is found
- All Tier 1 and 2 searches return null after 15+ queries
- Evidence suggests active deception or misinformation

---

_Pre-mortem completed. Proceeding to Tier 1 evidence gathering._
